Protein homeostasis is tightly regulated by the ubiquitin proteasome pathway. Disruption of this pathway gives rise to a host of neurological disorders. Through whole exome sequencing (WES) in families with neurodevelopmental disorders, we identified mutations in PSMD12, a core component of the proteasome, underlying a neurodevelopmental disorder with intellectual disability (ID) and features of autism spectrum disorder (ASD). We performed WES on six affected siblings from a multiplex family with ID and autistic features, the affected father, and two unaffected mothers, and a trio from a simplex family with one affected child with ID and periventricular nodular heterotopia. We identified an inherited heterozygous nonsense mutation in PSMD12 (NM_002816: c.367C>T: p.R123X) in the multiplex family and a de novo nonsense mutation in the same gene (NM_002816: c.601C>T: p.R201X) in the simplex family. PSMD12 encodes a non-ATPase regulatory subunit of the 26S proteasome. We confirm the association of PSMD12 with ID, present the first cases of inherited PSMD12 mutation, and demonstrate the heterogeneity of phenotypes associated with PSMD12 mutations.
| INTRODUCTION
The ubiquitin proteasome pathway (UPP) functions in protein turnover and ubiquitin-mediated signaling. Ubiquitination is a posttranslational modification that involves conjugating a ubiquitin moiety to target proteins through sequential steps mediated by three classes of enzymes:
ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, and ubiquitin ligases. In addition to its traditional role of targeting proteins for degradation, ubiquitination functions as a regulatory mechanism involved in various signaling processes in the cell.
Studies have shown that protein ubiquitination plays a key part in brain development, through the regulation of neuronal formation, migration, and maturation (Kawabe & Brose, 2011) . Furthermore, ubiquitin-like proteins, acetyl groups, and phosphate groups can be added to ubiquitin chains on substrate proteins leading to a complex post-translational ubiquitin code that directs the function and lifespan of the substrate (Swatek & Komander, 2016) . Following ubiquitination, substrate proteins are then targeted for degradation by the proteasome. The 26S proteasome consists of a 20S catalytic subunit responsible for substrate degradation, and a 19S regulatory subunit that facilitates interaction with the substrate and removal of the ubiquitin chain (da Fonseca, He, & Morris, 2012) . The regulatory subunit itself is composed of a base containing six ATPase subunits and two non-ATPase subunits, and a lid of 10 non-ATPase subunits. The proteasome functions in all eukaryotic cells to degrade substrate proteins through a highly regulated ATP and ubiquitin-dependent process (Bhattacharyya, Yu, Mim, & Matouschek, 2014) .
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder that affects~1% of the population. It is characterized by deficits in communication, diminished social skills, and stereotyped behaviors. The most common co-morbid condition with ASD is intellectual disability (ID), occurring in over 70% of individuals with ASD (Betancur, 2011) . ASD is highly heritable (Colvert et al., 2015; Sandin et al., 2014) and it is extremely heterogeneous, both phenotypically and genetically (Betancur, 2011; Mitchell, 2011) . It is estimated that hundreds of genes contribute to ASD risk, and genes identified to date encode molecules involved in a myriad of molecular pathways. Mutations in genes that encode for members of the UPP have been shown to result in a host of neurodevelopmental disorders with ASD and ID (Abrahams et al., 2013; Kanehisa & Goto, 2000) . Examples include disruptions in ubiquitin-conjugating enzymes (UBE2A mutations in syndromic X-linked ID [Nascimento, Otto, de Brouwer, & ViannaMorgante, 2006] , MIM 300860), ubiquitin ligases (UBE3A mutations in Angelman syndrome [Kishino, Lalande, & Wagstaff, 1997] (Küry et al., 2017) . Here we identify, using whole exome sequencing (WES), the first familial cases of inherited heterozygous mutations in PSMD12, and find that PSMD12 mutations are associated with a range of neuropsychiatric features including ASD and ID, and demonstrate and extend the heterogeneity of phenotypes arising from PSMD12 mutations.
| MATERIALS AND METHODS

| Subjects
Subjects were identified and evaluated in a clinical setting as having an unexplained neurodevelopmental disorder and referred for participation in a genetic research study. Peripheral blood samples were collected from the affected individuals and family members after obtaining written informed consent. Affected individuals of family AU28900 were evaluated by a team of clinicians (genetics, psychology, developmental pediatrics, and neurology) and assessed using the Goodenough-Harris Draw-A-Person Test (Goodenough, 1926; Goodenough & Harris, 1950; Harris, 1963) . The affected individual of family PH23300 was evaluated by a clinical geneticist.
| WES and data analysis
DNA samples were sequenced at the Broad Institute (Cambridge, MA). Exome enrichment was performed on 1 μg of whole blood genomic DNA using SureSelect v4 (Agilent Technologies, Santa Clara, CA), according to the manufacturer's protocol. The kit targets 98.2% of consensus coding sequences of the human exome. The captured, purified, and amplified library targeting the exome from each individual was sequenced on the Illumina HiSeq. Paired-end sequences were obtained at a read length of 72 bp.
Sequence analysis was performed according to a customized bio-
informatic pipeline using open-source tools for aligning reads, variant calling and annotation, and filtering out benign variation. Briefly, sequence reads were aligned to the reference human genome build GRCh37/hg19 using the Burrows-Wheeler Aligner (Li & Durbin, 2009 ). Alignments underwent base quality score recalibration, PCR duplicate removal, and realignment around indels. Variants were called using the Genome Analysis Toolkit (McKenna et al., 2010) and annotated using ANNOVAR (Wang, Li, & Hakonarson, 2010 
| RESULTS
In this study, we report on the identification of two nonsense mutations in PSMD12 in two families with ID, ASD, and PVNH.
| CLINICAL PRESENTATION
We ascertained two nonconsanguineous families, one of Middle Eastern descent with nine affected individuals (including the father; AU28900), and a second from the United States with one affected individual (PH23300; Figure 1 (a)). Affected individuals in family AU28900 presented with variable ID and autistic features (Figure 1 (a)). Family PH23300 consisted of a trio in which the proband presented with PVNH and mild developmental delay.
| Family AU28900
We identified a nonconsanguineous family of eight children in three branches that exhibit ASD and ID. The children share the same father (AU28905), who is also affected and is from the United Arab Emirates.
The mother of the first family branch is deceased and was of Indian ancestry; she and the father had two affected daughters. The mother of the second family branch (AU28911) is from the United Arab Emirates, and she and the father had three affected children, one son and two daughters. The mother of the third family branch (AU28904) is Omani, and she and the father had three affected children, one daughter and two sons.
Upon evaluation, the father (AU28905) of all of the children showed significant cognitive limitation. He attended school until fourth grade. He was immature for his age of about 42 years but was social with good eye contact and engagement. His speech was unclear and he was confused when asked about his age and the age of his children, though was able to name his occupation (janitor) and write his name in Arabic. Paying close attention to detail, he drew a simple picture of a man.
The first wife of AU28905 is deceased and her medical information was not available but she was reportedly unaffected. She and is another son, AU28903, who was diagnosed with autism and speech delay at 3 years of age. Evaluation of AU28903 at age 6 years 4 months of age revealed a head circumference of 52.5 cm (72nd percentile) and frontal bossing. He knew about 50 words and was more socially engaged than previously noted but his level of interaction was limited. He also displayed repetitive behaviors and poor eye contact.
It was reported that he does not accept variety in his diet. The medical information for the mother of these three children, AU28904, is not available but she is reportedly unaffected.
| Family PH23300
We identified a nonconsanguineous family from the United States with one daughter affected with PVNH and mild developmental delay.
The parents are reported to be healthy, as is an older maternal halfsister and a younger full sister. The affected daughter, PH23301, was noted to have intrauterine growth restriction and was the product of a premature vaginal delivery around 35-36 weeks gestation. Her birth weight was 1.87 kg (11th percentile for 35 weeks gestational age).
Whereas motor development was normal, she was reported to have mild cognitive and language delay. At 7 years 11 months of age her head circumference was 51.5 cm (48th percentile), height was 122 cm (21st percentile), and weight was 38.5 kg (98th percentile). Upon physical examination, she was noted to have mild ptosis, a very small mouth and normal muscle tone. There was no history of seizures. Clinical testing performed included a karyotype, array CGH, and FLNA sequencing, all of which were normal. Brain magnetic resonance imaging (MRI) at 7 years 6 months of age revealed multiple small PVNH in the lateral walls of the frontal horns and the anterior bodies of lateral ventricles (Figure 1(b) ). The cerebral ventricles were mildly enlarged, the anterior commissure was large, and there was slightly diminished white matter volume (Figure 1(b) ). 
| IDENTIFICATION OF THE DISEASE-CAUSING MUTATIONS
We performed WES in family AU28900 on six of the eight affected siblings, the affected father, and two unaffected mothers. The WES yielded a mean target coverage of 96% at ≥10× and a mean read depth of 83×. We identified an average of 27,305 variants,~95% of which were single nucleotide variants and 5% small insertions and deletions (indels; Table 1 ). We filtered for nonsynonymous variants that are rare with a minor allele frequency of less than 1% in several public databases of genomic variants (1000 Genomes Project, dbSNP135, NHLBI-GO Exome Sequencing Project, and ExAC) and an internal dataset of 831 whole exomes from the Middle Eastern population. Based on the pedigree structure and the segregation of the phenotype, we assumed a dominant mode of inheritance and focused on the remaining 513 heterozygous variants, of which 16 segregated with the phenotype and were potentially pathogenic (nonsynonymous, frameshift, at conserved splice site; Figure 2 ). Out of the 16 variants, the majority were missense mutations and only two had a predicted severe effect on protein, a nonsense mutation in PSMD12
(NM_002816: c.367C>T: p.R123X) and a loss of stop codon mutation in CLEC1A (NM_016511: c.A843G: p.X281W; Table 2 ). To systematically rule out nonpathogenic variants and narrow in on a diseasecausing mutation, we recruited extended family members and performed comprehensive Sanger sequencing of the 16 variants in all family members, including the two affected children that were not included in the original WES, AU28902 and AU28909 (Figure 1(a) and Table 2 ). Following this validation, we identified only one variant that segregated and validated: an inherited heterozygous nonsense mutation in PSMD12, (NM_002816: c.367C>T: p.R123X; Figure 3a ,b). To confirm the functional impact of the nonsense p.R123X mutation, we performed western blotting on lymphoblastoid cell lines from the affected father (AU28905) and unaffected mother (AU28904). We found that the mutation in the affected individual results in a reduction of PSMD12 protein expression compared to the unaffected control (Figure 3(c) ).
We then examined WES data from 433 other families with neurodevelopmental disorders in our study for potential mutations in PSMD12 and identified one additional allele in a simplex trio family, PH23300, with one child affected with mild developmental delay (Figure 1(a) ). WES on the affected child and both parents identified a rare de novo nonsense mutation in PSMD12 (NM_002816: c.601C>T:
p.R201X) in the affected child (PH23301; Figure 3(b) ). Brain MRI on PH23301 revealed multiple small PVNH in the lateral walls of the frontal horns and the anterior bodies of lateral ventricles. In addition, the cerebral ventricles were mildly enlarged, the anterior commissure was large, and there was slightly diminished white matter volume (Figure 1(b) ).
| DISCUSSION
We identified an inherited and a de novo nonsense mutation in PSMD12 in two families with ASD, ID, and PVNH. PSMD12 encodes a component of the regulatory subunit of the proteasome (Figure 3(a) ), a large multi-subunit enzymatic complex responsible for ATP-dependent, ubiquitin-mediated degradation of proteins. PSMD12 is a highly conserved, tightly regulated, non-ATPase component of the regulatory lid of the proteasome. The lid is responsible for proper substrate recognition, deubiquitination, and unfolding for subsequent translocation into the proteolytic cavity of the proteasome (Bedford, Paine, Sheppard, Mayer, & Roelofs, 2010) . PSMD12 is required for proper proteasome assembly and localization (Yen, Espiritu, & Chang, 2003) .
It is highly expressed in the brain based on data from the Allen Mouse
Brain Atlas of the Allen Institute for Brain Science. The gene is extremely intolerant to heterozygous loss of function mutations, with a pLI score of 1 according to ExAC (the ExAC database, containing WES data from 60,706 individuals); the closer pLI is to one, the higher the likelihood that a gene is intolerant to loss-of-function (pLI ≥ 0.9
indicates extreme intolerance to loss of function; Lek et al., 2016) .
Although the p.R123X mutation segregated with phenotype in family AU28900, there was one family member, AU28902, who was homozygous for the reference allele for every variant tested but nonetheless showed a mild learning disability without deficits in social behavior. The learning disability could potentially reflect being raised in a household where all other siblings have significant cognitive limitations.
Mutations in PSMD12 had not been associated with any human disorders, until a recent report of de novo mutations in a cohort with ID (Küry et al., 2017) . Table 3 mutations with ID. We describe the first case of a PSMD12 mutation being inherited in a dominant fashion, indicating that the condition does not exclusively occur de novo. By a near doubling of the total number of reported cases (from 10 to 19), we further refine the Whole exome sequencing and variant identification. WES in AU28900 was performed to a mean target coverage of 96% at ≥10× (left). Variant filtration and prioritization of WES data from AU28900. On average, we identified a total of 27,305 variants per exome, of which only one was nonsynonymous, rare, potentially pathogenic, segregated with phenotype, and was inherited (right) phenotype associated with PSMD12 mutations and describe additional associated features, including ASD and possibly PVNH, rather than only ID.
In our study, the p.R201X mutation was associated with PVNH but Küry et al. (2017) .
Mutations in genes encoding members of the UPP are associated with ASD and ID. Importantly, modulators of the proteasome system are already being explored as cancer therapies (Micel, Tentler, Smith, & Eckhardt, 2013; Tsukamoto & Yokosawa, 2009) , making the UPP a pharmacologically accessible target for ASD therapies that explore strategies using these modulators. Only~56% of ASD-associated UPP genes have phenotyped mouse models, and only eight phenotypic descriptions report abnormalities of brain development, morphology, or altered behavior (Eppig et al., 2015) . Thus future work in animal models will be crucial to understand the underlying molecular mechanisms in this class of ASD-associated genes. Interestingly, recent work suggests that PSMD12 is a transcriptional target of CHD8 in human neural stem cells (Cotney et al., 2015) . CHD8, chromodomain helicase DNA-binding protein 8, is one of the most penetrant ASD genes identified through several large-scale WES studies (Iossifov et al., 2012; Neale et al., 2012; O'Roak, Vives, Fu, et al., 2012; O'Roak, Vives, Girirajan, et al., 2012; Sanders et al., 2012) . It encodes an ATP-dependent chromatin remodeler of the SNF2 family. PSMD12 was also reported to be upregulated in rat fetal brain in response to maternal immune activation (Lombardo et al., 2018) . The mechanism of how PSMD12
haploinsufficiency gives rise to the neurodevelopmental phenotype remains under investigation, and future functional studies will be required to address this.
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